
CA 15-3: A <a href="https://www.medicinenet.com/tumor_grade/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">tumor</a> marker most useful in following the course of treatment in women diagnosed with <a href="https://www.medicinenet.com/breast_cancer_facts_stages/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">breast cancer</a>, especially advanced <a href="https://www.medicinenet.com/breast_anatomy/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">breast</a> <a href="https://www.medicinenet.com/cancer/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">cancer</a>. CA 15-3 levels are rarely elevated in women with early stage breast cancer. 
Cancers of the ovary, lung, and prostate may also raise CA 15-3 levels. Elevated levels of CA 15-3 may be associated with noncancerous conditions, such as benign breast or ovarian disease, <a href="https://www.medicinenet.com/endometriosis/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">endometriosis</a>, <a href="https://www.medicinenet.com/pelvic_inflammatory_disease/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">pelvic inflammatory disease</a>, and hepatitis. <a href="https://www.medicinenet.com/pregnancy/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">Pregnancy</a> and lactation can also cause CA 15-3 levels to rise.